2013

NIH launches regional Stroke Trials Network

Wednesday, December 18, 2013

The National Institutes of Health has launched a network of 25 regional stroke centers working with nearby satellite facilities spanning the country. They will include teams of researchers representing every medical specialty needed for stroke care and will address the three prongs of stroke research: prevention, treatment and recovery.

[Read More]

New presurgery combination therapy for triple-negative breast cancer

Tuesday, December 17, 2013

The I-SPY 2 trial, an innovative, multidrug, phase II breast cancer trial, has yielded positive results with the first drug to complete testing in the trial. Adding the chemotherapy carboplatin and the molecularly targeted drug veliparib to standard presurgery chemotherapy improved outcomes for women with triple-negative breast cancer.

[Read More]

Bridgepoint Development Capital to acquire Quotient Clinical

Monday, December 16, 2013

Quotient Clinical, a provider of outsourced, early stage drug development services to the pharmaceutical industry, has been acquired from the Quotient Bioresearch Group by Bridgepoint Development Capital for an undisclosed sum. Employing over 200 people, Quotient Clinical has developed a platform which offers an integrated approach to formulation development, “real-time” drug product manufacturing and clinical testing. Using this platform has been proven to significantly reduce the time and cost of the early stage drug development process.

[Read More]

BIND Therapeutics, Amgen amend collaboration agreement

Monday, December 16, 2013

BIND Therapeutics, a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins, has amended its development and commercialization collaboration agreement with Amgen, to extend the period during which Amgen may exercise its option by six months. BIND entered into a global collaboration agreement with Amgen on Jan. 7, to develop and commercialize a kinase inhibitor nanomedicine for treating a range of solid tumors based on BIND’s platform for targeted and programmable nanomedicines and Amgen’s undisclosed proprietary kinase inhibitor. Amgen had 12 months to exercise its option to select a novel Accurin candidate for further development. The option period under the amended collaboration agreement has been extended to July 7, 2014 to allow for completion of the research plan. No other terms of the original agreement have been changed.

[Read More]